OssDsign reached the commercial milestone of 200 implants in France since entering the market in late 2019.
In 2019, the French health authorities granted product reimbursement for the OssDsign Cranial PSI implant. During the following years, OssDsign established an initial sales presence, secured first sales and later gained broader market access by winning numerous tenders. In early 2022, OssDsign decided to further increase focus on France and restructured its commercial presence accordingly, leading to sales acceleration in the second half of 2022 – ultimately allowing the company to reach the 200 implant milestone within only a few years.
OssDsign Cranial PSI is a patient-specific cranial implant made from 3D-printed medical-grade titanium covered by a regenerative calcium phosphate composition. While the titanium skeleton reinforces the implant and resists physical and mechanical stress, the calcium phosphate composition provides healing and regenerative properties, allowing regrowth of the patient’s own bone. Over time, the calcium phosphate composition degrades and is replaced with bone.
“This commercial milestone highlights the speed at which we have established OssDsign Cranial PSI in France, turning the French market into a solid business and growth platform with major tenders secured and many recurring users – all during a three-year period strongly influenced by a pandemic. We have therefore clearly demonstrated that by combining a highly differentiated technology offering with a focused go-to-market model, we have a recipe for future growth,” said Morten Henneveld, CEO of OssDsign.
OssDsign reached the commercial milestone of 200 implants in France since entering the market in late 2019.
In 2019, the French health authorities granted product reimbursement for the OssDsign Cranial PSI implant. During the following years, OssDsign established an initial sales presence, secured first sales and later gained broader market...
OssDsign reached the commercial milestone of 200 implants in France since entering the market in late 2019.
In 2019, the French health authorities granted product reimbursement for the OssDsign Cranial PSI implant. During the following years, OssDsign established an initial sales presence, secured first sales and later gained broader market access by winning numerous tenders. In early 2022, OssDsign decided to further increase focus on France and restructured its commercial presence accordingly, leading to sales acceleration in the second half of 2022 – ultimately allowing the company to reach the 200 implant milestone within only a few years.
OssDsign Cranial PSI is a patient-specific cranial implant made from 3D-printed medical-grade titanium covered by a regenerative calcium phosphate composition. While the titanium skeleton reinforces the implant and resists physical and mechanical stress, the calcium phosphate composition provides healing and regenerative properties, allowing regrowth of the patient’s own bone. Over time, the calcium phosphate composition degrades and is replaced with bone.
“This commercial milestone highlights the speed at which we have established OssDsign Cranial PSI in France, turning the French market into a solid business and growth platform with major tenders secured and many recurring users – all during a three-year period strongly influenced by a pandemic. We have therefore clearly demonstrated that by combining a highly differentiated technology offering with a focused go-to-market model, we have a recipe for future growth,” said Morten Henneveld, CEO of OssDsign.
Copy to clipboard 
